Ethotoin
Peganone (ethotoin) is a small molecule pharmaceutical. Ethotoin was first approved as Peganone on 1982-01-01. It is used to treat complex partial epilepsy, epilepsy, seizures, and tonic-clonic epilepsy in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ethotoin
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PEGANONE | Recordati | N-010841 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
complex partial epilepsy | EFO_1000877 | D017029 | — |
epilepsy | EFO_0000474 | D004827 | G40.9 |
seizures | HP_0007359 | D012640 | G40.4 |
tonic-clonic epilepsy | EFO_0007262 | D004830 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | 1 | — | 1 | 2 |
Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 1 | 1 | — | — | 2 |
Seizures | D012640 | G40.4 | — | — | 1 | — | — | 1 | |
Absence epilepsy | D004832 | G40.A | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuralgia | D009437 | EFO_0009430 | — | 2 | — | — | — | 2 | |
Complex regional pain syndromes | D020918 | EFO_1001998 | — | 1 | — | — | — | 1 | |
Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
Peripheral nervous system diseases | D010523 | G64 | — | 1 | — | — | — | 1 | |
Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Treatment-resistant depressive disorder | D061218 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ETHOTOIN |
INN | ethotoin |
Description | Ethotoin is an imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective. It has a role as an anticonvulsant. |
Classification | Small molecule |
Drug class | antiepileptics (hydantoin derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCN1C(=O)NC(c2ccccc2)C1=O |
Identifiers
PDB | — |
CAS-ID | 86-35-1 |
RxCUI | 4136 |
ChEMBL ID | CHEMBL1095 |
ChEBI ID | 4888 |
PubChem CID | 3292 |
DrugBank | DB00754 |
UNII ID | 46QG38NC4U (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 116 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
985 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more